benzyl 4-(5-formyl-1-tosyl-1H-indol-4-yl)piperazine-1-carboxylate | 1258408-31-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: benzyl 4-(5-formyl-1-tosyl-1H-indol-4-yl)piperazine-1-carboxylate
• 英文别名: benzyl 4-[5-formyl-1-(4-methylphenyl)sulfonylindol-4-yl]piperazine-1-carboxylate
• CAS: 1258408-31-9
• 化学式: C₂₈H₂₇N₃O₅S
• 分子量: 517.605
• InChiKey: AZXFIYIZWBKPBM-UHFFFAOYSA-N

物化性质

• 沸点：
  736.4±70.0 °C(Predicted)
• 密度：
  1.31±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.3
• 重原子数：
  37
• 可旋转键数：
  7
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.21
• 拓扑面积：
  97.3
• 氢给体数：
  0
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  benzyl 4-(5-formyl-1-tosyl-1H-indol-4-yl)piperazine-1-carboxylate 、 对甲苯磺酰肼 以 甲苯 为溶剂， 反应 3.0h， 生成
  参考文献：
  名称：

  Syntheses of aza-analogous iso-ergoline scaffolds using carbene mediated C–H insertion

  摘要：

  A novel direct flexible and robust approach to the iso-ergoline tetracyclic system in which a five or six-membered ring is established by intramolecular carbene C-H insertion is reported The protocol involves a two step conversion of an aromatic aldehyde to the corresponding hydrazone and without purification further conversion to the diazo-compound followed by thermal carbene formation and C-H insertion alpha to a nitrogen (C) 2010 Elsevier Ltd All rights reserved

  DOI：

  10.1016/j.tet.2010.09.023
• 作为产物：
  描述：

  4-piperazin-1-yl-1H-indole dihydrochloride 在 苄基三乙基氯化铵 、 sodium hydroxide 、 三氯氧磷 作用下， 以 四氢呋喃 、 水 、 甲苯 为溶剂， 反应 5.25h， 生成 benzyl 4-(5-formyl-1-tosyl-1H-indol-4-yl)piperazine-1-carboxylate
  参考文献：
  名称：

  [EN] NOVEL 6,6A,7,8,9,10-HEXAHYDRO-4H-4,8,10A-TRIAZA-ACEPHENANTHRYLENE DERIVATIVES AS DOPAMINE D2 LIGANDS
  [FR] NOUVEAUX DÉRIVÉS 6,6A,7,8,9,10-HEXAHYDRO-4H-4,8,10A-TRIAZA-ACÉPHÉNANTHRYLÈNE EN TANT QUE LIGANDS DES RÉCEPTEURS D2 DE LA DOPAMINE

  摘要：

  这项发明涉及多巴胺D2受体配体化合物。该发明提供了一种包括该发明化合物的治疗有效量和药用载体的药物组合物。本发明还提供了制备式I或式II化合物或其药用可接受盐的方法。本发明还提供了一种治疗患有神经退行性疾病的受试者的方法，包括向受试者施用式I或式II化合物或其药用可接受盐的治疗有效量。本发明还提供了一种治疗患有精神障碍的受试者的方法，包括向受试者施用式I或式II化合物或其药用可接受盐的治疗有效量。

  公开号：

  WO2011088838A1

文献信息

• [EN] NOVEL 6,6A,7,8,9,10-HEXAHYDRO-4H-4,8,10A-TRIAZA-ACEPHENANTHRYLENE DERIVATIVES AS DOPAMINE D2 LIGANDS<br/>[FR] NOUVEAUX DÉRIVÉS 6,6A,7,8,9,10-HEXAHYDRO-4H-4,8,10A-TRIAZA-ACÉPHÉNANTHRYLÈNE EN TANT QUE LIGANDS DES RÉCEPTEURS D2 DE LA DOPAMINE
  申请人：LUNDBECK & CO AS H

  公开号：WO2011088838A1

  公开（公告）日：2011-07-28

  This invention is directed to compounds, which are dopamine D2 ligands. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. The present invention also provides processes for the preparation of the compounds of formula I or formula II, or a pharmaceutically acceptable salt thereof. The present invention further provides a method of treating a subject suffering from a neurodegenerative disorder comprising administering to the subject a therapeutically effective amount of a compound of formula I or formula II, or a pharmaceutically acceptable salt thereof. The present invention further provides a method of treating a subject suffering from a psychiatric disorder comprising administering to the subject a therapeutically effective amount of a compound of formula I or formula II, or a pharmaceutically acceptable salt thereof.

  这项发明涉及多巴胺D2受体配体化合物。该发明提供了一种包括该发明化合物的治疗有效量和药用载体的药物组合物。本发明还提供了制备式I或式II化合物或其药用可接受盐的方法。本发明还提供了一种治疗患有神经退行性疾病的受试者的方法，包括向受试者施用式I或式II化合物或其药用可接受盐的治疗有效量。本发明还提供了一种治疗患有精神障碍的受试者的方法，包括向受试者施用式I或式II化合物或其药用可接受盐的治疗有效量。
• Syntheses of aza-analogous iso-ergoline scaffolds using carbene mediated C–H insertion
  作者：Niels Krogsgaard-Larsen、Mikael Begtrup、Karla Frydenvang、Jan Kehler

  DOI：10.1016/j.tet.2010.09.023

  日期：2010.11

  A novel direct flexible and robust approach to the iso-ergoline tetracyclic system in which a five or six-membered ring is established by intramolecular carbene C-H insertion is reported The protocol involves a two step conversion of an aromatic aldehyde to the corresponding hydrazone and without purification further conversion to the diazo-compound followed by thermal carbene formation and C-H insertion alpha to a nitrogen (C) 2010 Elsevier Ltd All rights reserved
• [EN] NOVEL 4-(ARYL-4-SULFONYL)-6,6a,7,8,9,10-HEXAHYDRO-4H-4,8,10a-TRIAZA-ACEPHENANTHRYLENE AND 3-ARYLSULFONYL-6,6a,7,8,9,10-HEXAHYDRO-3H-3,8,10a-TRIAZA-CYCLOPENTA[C]FLUORENE DERIVATIVES AS SEROTONIN 5-HT6 LIGANDS<br/>[FR] NOUVEAUX DÉRIVÉS DE 4-(ARYL-4-SULFONYL)-6,6A,7,8,9,10-HEXAHYDRO-4H-4,8,10A-TRIAZA-ACÉPHÉNANTHRYLÈNE ET 3-ARYLSULFONYL-6,6A,7,8,9,10-HEXAHYDRO-3H-3,8,10A-TRIAZA-CYCLOPENTA[C]FLUORÈNE EN TANT QUE LIGANDS DE SÉROTONINE 5-HT6
  申请人：LUNDBECK & CO AS H

  公开号：WO2011088836A1

  公开（公告）日：2011-07-28

  This invention is directed to compounds of formula I or II, which are serotonin 5-HT 6 ligands. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. The present invention also provides processes for the preparation of the compounds of formula I or II, or a pharmaceutically acceptable salt thereof. The present invention further provides a method of treating a subject suffering from a neurodegenerative disorder comprising administering to the subject a therapeutically effective amount of a compound of formula I or II, or a pharmaceutically acceptable salt thereof. The present invention further provides a method of treating a subject suffering from a psychiatric disorder comprising administering to the subject a therapeutically effective amount of a compound of formula I or II, or a pharmaceutically acceptable salt thereof.

  本发明涉及式I或II的化合物，它们是血清素5-HT6受体配体。本发明提供了一种药物组合物，其包含本发明的化合物以及药学上可接受的载体的治疗有效量。本发明还提供了制备式I或II的化合物或其药学上可接受的盐的方法。本发明进一步提供了一种治疗患有神经退行性疾病的受试者的方法，包括向该受试者施用式I或II的化合物或其药学上可接受的盐的治疗有效量。本发明还提供了一种治疗患有精神疾病的受试者的方法，包括向该受试者施用式I或II的化合物或其药学上可接受的盐的治疗有效量。